Sector: Health Care
Director information for MASIMO CORP (data for year 2025)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Bill Jellison | Independent Director | 67 | [] | [] | 2025 |
| Catherine Szyman | CEO; Chief Executive Officer and Director | 58 | ["Has served as CEO of the Company since February 12, 2025", "President of Advanced Patient Monitoring Business (APM) at Edwards Lifesciences / Becton Dickinson from 2015 to 2025", "Inari Medical, Inc. (2019\u2013Present)", "Outset Medical, Inc. (2021\u20132024)", "Experienced global executive and board member with strategy, operating and finance leadership experience", "Inspirational leader with over 20 years of experience leading and transforming businesses through patient-focused innovation", "Deep Medical Device, and Operational experience developed during her roles at Medtronic, Edwards Lifescience and Becton Dickinson", "Successful track record of accelerating revenue growth by bringing new products to market", "Extensive experience leading and retaining top industry talent", "Deep existing relationships within the sector", "Over a decade of experience in Critical Care business at Edwards Lifesciences", "Led revenue growth through AI-driven solutions", "More than 20 years at Medtronic with leadership roles in corporate strategy, business development, and finance", "Served on the boards of Inari Medical and Outset Medical", "B.A. from the University of St. Thomas and M.B.A. from Harvard Business School"] | [] | 2025 |
| Craig Reynolds | Director | 76 | ["Board of Directors and executive officer experience in the healthcare and medical device industry, including Chairman, CEO and COO roles", "Deep understanding of industrial management and strategy", "Wealth of experience in medical device products at a wide variety of medical device companies"] | [] | 2025 |
| Darlene Solomon | Independent Director | 66 | ["Senior Vice President and Chief Technology Officer of Agilent Technologies from 2006\u20132023", "Member of the National Academy of Engineering and serves on multiple academic and government advisory boards focused on science, technology, and innovation", "Senior Vice President and Chief Technology Officer of Agilent Technologies, Inc. from 2006 until July 2023", "Director of the Life Sciences Technologies Laboratory at Agilent", "Senior director, research and development/technology for Agilent\u2019s Life Sciences and Chemical Analysis business", "Vice President, Agilent Laboratories (2003 \u2013 2006)", "Bachelor\u2019s degree in Chemistry from Stanford University", "Ph.D. in Inorganic Chemistry from MIT", "Experienced public company board director", "Expertise in corporate governance, business transformation, and high-tech industry", "Perspective in strategy, innovation, teamwork, and digital leadership"] | ["Compensation", "Nominating, Compliance and Corporate Governance", "Business Risk & Review"] | 2025 |
| Joe Kiani | Former Chief Executive Officer and Chairman of the Board | 60 | [] | [] | 2025 |
| Michelle Brennan | Former Interim CEO; Chairman of the Board; Chairman, Independent Director; Former Interim Chief Executive Officer and Director | 59 | ["Over 30 years of business experience in the healthcare industry", "Previously served in various positions at Johnson & Johnson, including Global Value Creation Leader and Company Group Chair of Medical Devices in Europe, the Middle East, and Africa", "Cardinal Health Inc. (2022\u2013present)", "Coupa Software Inc. (2020\u20132023)", "Deep Operational experience in Medical Devices: Company Group Chair of Medical Devices in Europe, the Middle East, and Africa (\u201cEMEA\u201d) from 2015 to December 2018 at Johnson & Johnson", "Broad understanding of Masimo developed as Interim CEO", "Over 30 years of experience in various roles at Johnson & Johnson"] | ["Business Risk & Review", "Audit Committee", "Human Resources & Compensation Committee"] | 2025 |
| Quentin Koffey | Managing Partner and Chief Investment Officer; Vice-Chairman of the Board | 46 | ["Currently serves as Managing Partner and Chief Investment Officer at Politan Capital Management LP", "Previously served as a Partner at Senator Investment Group LP, a Portfolio Manager for Strategic Investments at The D.E. Shaw Group and a Portfolio Manager at Elliott Management Corporation", "Azenta, Inc. (2024\u2013present)", "Expertise as a professional investor", "Managing Partner and Chief Investment Officer of Politan Capital Management LP since 2021", "Partner at Senator Investment Group LP (2019 \u2013 2021)", "Portfolio Manager, Strategic Investments at D.E. Shaw Group (2017 \u2013 2019)", "Portfolio Manager at Elliott Management Corporation (2010 \u2013 2017)", "B.A. from Yale College", "J.D. from Stanford Law School", "M.B.A. from Stanford Graduate School of Business", "Strong track record of working constructively with boards and management teams to enhance stockholder value", "Deep Masimo understanding and experience developed as serving as Lead Independent Director and Vice-Chairman"] | ["Audit", "Compensation", "Nominating, Compliance and Corporate Governance, Chairman", "Business Risk & Review", "Nominating, Compliance and Corporate Governance"] | 2025 |
| Robert Chapek | Chairman of the Board | 65 | ["Nearly 30 years of experience in the media and consumer industry", "Prior Executive Officer experience at a Fortune 500 company", "Deep understanding of global operations in the consumer industry"] | ["Audit"] | 2025 |
| Timothy Scannell | Independent Director | ["Over 30 years of experience in delivering market-leading results at Stryker Corporation", "Served as President and Chief Operating Officer of Stryker from 2018 to 2021", "Group President for Stryker\u2019s MedSurg & Neurotechnology businesses for ten years", "Various leadership roles at Stryker including General Manager and Vice President", "Holds a bachelor\u2019s degree in Business Administration and Marketing and an M.B.A from the University of Notre Dame", "Deep Medical Device and Operational experience", "Serves on the boards of several private companies including Regenity Biosciences, Synaptive Medical, and CereVasc, Inc.", "Current board member at Novocure Limited (2021\u2013present) and Insulet Corporation (2014\u2013present)", "Prior board service at EXACT Sciences Corp., Molekule Group, Inc., and Renalytix Plc"] | ["Compensation", "Business Risk & Review"] | 2025 | |
| Tim Scannell | Independent Director | 60 | ["President and Chief Operating Officer of Stryker from 2018 to 2021", "Group President for Stryker\u2019s MedSurg & Neurotechnology businesses for ten years"] | ["Compensation", "Business Risk & Review"] | 2025 |
| Wendy Lane | Independent Director | 73 | ["Experienced public company director, who has served on and/or chaired seven audit as well as other committees", "Currently serves as a director of Verisk Analytics, Inc., YourBio Health, Inc., and CAC Holdings, LLC", "more than 30 years of board experience with 15 companies", "oversaw strategic, operational, and financial changes at public companies", "extensive experience in the insurance and information services industries", "15 years in the investment banking industry", "expertise in transformational change, crisis management, finance, M&A, compensation, human capital, audit, and corporate governance", "Experienced public company director and corporate governance expert who has sat on and/or chaired seven audit committees"] | ["Nominating, Compliance and Corporate Governance", "Business Risk & Review"] | 2025 |
| William Jellison | Independent Director | 67 | ["Over 40 years of business experience including extensive experience in the medical technology industry", "Previously served as Vice President and Chief Financial Officer of Stryker Corporation", "Over 40 years of business experience in the medical technology industry", "Independent business consultant and M&A advisor", "Former Vice President and Chief Financial Officer of Stryker Corporation", "Senior Vice President & Chief Financial Officer of Dentsply International", "Holds a B.A. in Business Administration from Hope College"] | ["Audit", "Compensation", "Nominating, Compliance and Corporate Governance", "Business Risk & Review"] | 2025 |
